460 related articles for article (PubMed ID: 27391346)
21. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
[TBL] [Abstract][Full Text] [Related]
22. Ikaros and leukaemia.
Olsson L; Johansson B
Br J Haematol; 2015 May; 169(4):479-91. PubMed ID: 25753742
[TBL] [Abstract][Full Text] [Related]
23. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
[TBL] [Abstract][Full Text] [Related]
24. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
25. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
26. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
29. Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia.
Ge Z; Gu Y; Han Q; Zhao G; Li M; Li J; Chen B; Sun T; Dovat S; Gale RP; Song C
Sci Rep; 2016 Nov; 6():38004. PubMed ID: 27885263
[TBL] [Abstract][Full Text] [Related]
30. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
Song C; Ge Z; Ding Y; Tan BH; Desai D; Gowda K; Amin S; Gowda R; Robertson GP; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Gurel Z; Iyer S; Dhanyamraju PK; Xiang M; Kawasawa YI; Cury NM; Yunes JA; McGrath M; Schramm J; Su R; Yang Y; Zhao Z; Lyu X; Muschen M; Payne KJ; Gowda C; Dovat S
Blood; 2020 Sep; 136(13):1520-1534. PubMed ID: 32396934
[TBL] [Abstract][Full Text] [Related]
31. IKZF1
Kovach AE; Wengyn M; Vu MH; Doan A; Raca G; Bhojwani D
Pediatr Blood Cancer; 2024 Jul; 71(7):e30996. PubMed ID: 38637852
[TBL] [Abstract][Full Text] [Related]
32. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
35. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
36. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
[TBL] [Abstract][Full Text] [Related]
37. IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia.
Maciel ALT; Barbosa TDC; Blunck CB; Wolch K; Machado AAL; da Costa ES; Bergier LL; Schramm MT; Ikoma-Coltutato MRV; Lins MM; Aguiar TF; Mansur MB; Emerenciano M
Transl Oncol; 2022 Jan; 15(1):101291. PubMed ID: 34826720
[TBL] [Abstract][Full Text] [Related]
38. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
39. The molecular genetic makeup of acute lymphoblastic leukemia.
Mullighan CG
Hematology Am Soc Hematol Educ Program; 2012; 2012():389-96. PubMed ID: 23233609
[TBL] [Abstract][Full Text] [Related]
40. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
Chiaretti S; Brugnoletti F; Messina M; Paoloni F; Fedullo AL; Piciocchi A; Elia L; Vitale A; Mauro E; Ferrara F; De Fabritiis P; Luppi M; Ronco F; De Propris MS; Raponi S; Kronnie GT; Vignetti M; Guarini A; Foà R
Leuk Res; 2016 Feb; 41():36-42. PubMed ID: 26754556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
